[ CAS No. 137129-98-7 ] {[proInfo.proName]}

Name: 137129-98-7|6-Chloro-2-methylnicotinic acid|98%
Brand: Ambeed
SKU: A392490
Price: 5.0 USD
Availability: InStock
Rating: 98 (28 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 137129-98-7

Structure of 137129-98-7 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 137129-98-7 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 137129-98-7 ]

SDS Specification

Alternatived Products of [ 137129-98-7 ]

Product Details of [ 137129-98-7 ]

CAS No. :	137129-98-7	MDL No. :	MFCD09842452
Formula :	C₇H₆ClNO₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	SGHDEIVHYSOLRC-UHFFFAOYSA-N
M.W :	171.58	Pubchem ID :	46223839
Synonyms :

Calculated chemistry of [ 137129-98-7 ]

Physicochemical Properties

Num. heavy atoms :	11
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.14
Num. rotatable bonds :	1
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	41.17
TPSA :	50.19 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.11 cm/s

Lipophilicity

Log Po/w (iLOGP) :	0.62
Log Po/w (XLOGP3) :	1.74
Log Po/w (WLOGP) :	1.74
Log Po/w (MLOGP) :	-0.18
Log Po/w (SILICOS-IT) :	1.82
Consensus Log Po/w :	1.15

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.56

Water Solubility

Log S (ESOL) :	-2.34
Solubility :	0.789 mg/ml ; 0.0046 mol/l
Class :	Soluble
Log S (Ali) :	-2.41
Solubility :	0.666 mg/ml ; 0.00388 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-2.4
Solubility :	0.688 mg/ml ; 0.00401 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.58

Safety of [ 137129-98-7 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 137129-98-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 137129-98-7 ]
Downstream synthetic route of [ 137129-98-7 ]

[ 137129-98-7 ] Synthesis Path-Upstream 1~2

1
[ 137129-98-7 ]
[ 164666-68-6 ]

Reference： [1] Patent: WO2017/162524, 2017, A1,

2
[ 31163-12-9 ]
[ 137129-98-7 ]

Reference： [1] Journal of Medicinal Chemistry, 2010, vol. 53, # 9, p. 3814 - 3830
[2] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 22, p. 6748 - 6753

[ 137129-98-7 ] Synthesis Path-Downstream 1~33

1
[ 137129-98-7 ]
[ 108-91-8 ]
[ 1024037-43-1 ]

Yield	Reaction Conditions	Operation in experiment
77%		Intermediate 55; 6-chloro-N-cyclohexyl-2-methylnicotinamide; A solution of <strong>[137129-98-7]2-methyl-6-chloronicotinic acid</strong> (300 mg, 1.75 mmol) and 1-hydroxybenzotriazole (260 mg, 1.92 mmol) was stirred in dichloromethane (25 ml) then triethylamine (561 ul, 4.02 mmol) and EDAC (401 mg, 2.1 mmol) were added and stirred for 5 minutes then cyclohexylamine (201 ul, 1.75 mmol) was added and the reaction was stirred for a further 16 hours at room temperature. The reaction was diluted with dichloromethane (25 ml), washed with sat. NaHCO3, 1M HCl, water, brine and dried over MgSO4, filtered and the solvent evaporated to give 6-chloro-2-methyl-N-cyclohexylnicotinamide (340 mg, 77%) as a fawn coloured powder1H NMR (400.13 MHz, DMSO-d6) delta1.23 (5H, d), 1.58 (1H, s), 1.70-1.74 (2H, m), 1.82-1.85 (2H, m), 2.47 (3H, s), 3.72 (1H, t), 7.39 (1H, d), 7.73 (1H, d), 8.37 (1H, d)MS m/e (M+H)+253

Reference： [1]Patent: US2008/269288,2008,A1 .Location in patent: Page/Page column 82

2
[ 137129-98-7 ]
[ 1204535-11-4 ]
[ 1204535-71-6 ]

Yield	Reaction Conditions	Operation in experiment
		HATU (460 mg, 1.21 mmol) was added to a solution of <strong>[137129-98-7]6-chloro-2-methyl-3-pyridinecarboxylic acid</strong> (commercially available, e.g. from Anichem, or may be prepared according to known methods) (173 mg, 1.01 mmol) in DMF (4 ml) and the mixture was treated with DIPEA (0.440 ml, 2.52 mmol). This mixture was stirred for ca. 10 min at ambient temperature. (3S)-3-Methyl-1-[4-(trifluoromethyl)phenyl]sulfonyl}piperazine (may be prepared as described in Description 2) (371 mg, 1.20 mmol) was then added and stirring was continued for one hour. The reaction mixture was partitioned between DCM and sat aq. NaHCO3 solution (20 ml each). The layers were separated and the aqueous was washed with further DCM (2×20 ml). The combined organic layers were concentrated to leave a dark brown gum. Purification by silica chromatography (Biotage SP4, 25S cartridge), eluting with 12-100% ethyl acetate in isohexane, gave the title compound (456 mg) as a pale yellow gum.m/z (API-ES) 462/464 [M+H]+ (Cl isotopes)

Reference： [1]Patent: US2010/22555,2010,A1 .Location in patent: Page/Page column 26

3
[ 137129-98-7 ]
[ 1204535-20-5 ]
[ 1204535-72-7 ]

Yield	Reaction Conditions	Operation in experiment
		HATU (425 mg, 1.12 mmol) was added to a solution of <strong>[137129-98-7]6-chloro-2-methyl-3-pyridinecarboxylic acid</strong> (commercially available, e.g. from Anichem, or may be prepared according to known methods) (160 mg, 0.93 mmol) in DMF (3 ml) and the mixture was treated with DIPEA (0.407 ml, 2.33 mmol). This mixture was stirred for ca. 10 min at ambient temperature. 3-Methyl-4-[(3S)-3-methyl-1-piperazinyl]sulfonyl}benzonitrile (may be prepared as described in Description 11) (313 mg, 1.12 mmol) was added as a solution in DMF (2 ml) and stirring was continued for ca. 1 hour. The reaction mixture was partitioned between DCM and sat aq. NaHCO3 solution (20 ml each). The layers were separated and the aqueous was washed with further DCM (2×20 ml). The combined organic layers were dried (hydrophobic frit) and concentrated to leave a dark brown gum. Purification by silica chromatography (Biotage SP4, 25S cartridge), eluting with 12-100% ethyl acetate in isohexane, gave the title compound as a pale cream foam (376 mg).m/z (API-ES) 433/435 [M+H]+ (Cl isotopes)

Reference： [1]Patent: US2010/22555,2010,A1 .Location in patent: Page/Page column 26

4
[ 137129-98-7 ]
[ 62366-52-3 ]

Reference： [1]Journal of Medicinal Chemistry,2010,vol. 53,p. 3814 - 3830

5
[ 31163-12-9 ]
[ 137129-98-7 ]

Reference： [1]Journal of Medicinal Chemistry,2010,vol. 53,p. 3814 - 3830
[2]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 6748 - 6753

6
[ 879088-41-2 ]
[ 137129-98-7 ]
[ 879088-87-6 ]